[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598611":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":31,"collaborators":24,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":24,"maxAge":24,"enrollmentInfo":43,"targetDuration":24,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":59,"whyStopped":24,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":24},{"fullName":5,"class":6},"Charles University, Czech Republic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CLaCS with 70% Glucose (Control Group)","ACTIVE_COMPARATOR","Participants in this group will undergo the CLaCS procedure using Nd:YAG 1064 nm laser followed by intravascular injection of 70% glucose as the sclerosant. This represents the standard CLaCS protocol and serves as the control arm.",[13],"Procedure: CLaCS",{"label":15,"type":10,"description":16,"interventionNames":17},"CLaCS with 0.2% Polidocanol Foam (Aetoxysklerol) - Test Group","Participants in this group will receive the same laser treatment (Nd:YAG 1064 nm) as the control group, but the sclerosant will be a 0.2% polidocanol foam, prepared using the VARIXIO system. This arm evaluates the efficacy of a low-concentration detergent-based alternative.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","CLaCS","CLaCS is hybrid outpatient procedure combining Nd:YAG 1064 nm laser treatment with injection of a sclerosant (either 70% glucose or 0.2% polidocanol foam).",[15,9],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Peter Balaz, professor","CONTACT","+420776882216","balazp@fnkv.cz",{"type":32,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100598611","phase-2-clacs-using-02-aetoxysklerol-foam-and-70-glucose-for-the-treatment-of-lower-limb-telangiectasias-100598611",false,"NCT07073742","CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias","Randomized, Controlled, Non-Inferiority Trial on the Efficacy of CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias","CLACSO","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Age \\> 18 years.\n3. CEAP classification C1 (telangiectasias only).\n4. Treated area for the study must be ≤ 20x20 cm on the lower limb - thigh.\n\nExclusion Criteria:\n\n1. Reflux in trunk veins or perforators.\n2. Active skin infection at the treatment site.\n3. Presence of reticular veins.\n4. Previous sclerotherapy\u002FCLaCS in the target area.",true,"ALL",{"count":44,"type":45},240,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","This randomized, controlled, non-inferiority trial aims to compare the efficacy of two sclerosants used in the CLaCS (CryoLaser and CryoSclerotherapy) method for treating telangiectasias and reticular varicose veins. CLaCS is an advanced outpatient procedure that combines Nd\\\\:YAG laser treatment with sclerotherapy to enhance vein closure and cosmetic outcomes while minimizing side effects. The trial will compare the standard 70% glucose sclerosant with a novel 0.2% Aetoxysklerol (polidocanol) foam prepared using the VARIXIO system. Despite widespread use of CLaCS, no head-to-head studies currently exist comparing these two agents. This study aims to determine whether low-concentration Aetoxysklerol foam is non-inferior to 70% glucose in achieving effective telangiectasia elimination.",[51,52,53],"Varicose Veins of Lower Limb","Spider Veins","Reticular Leg Veins",[55,56,57,58],"Telangiectasia","CryoLaser and CryoSclerotherapy","Cosmetic phlebology","AI prediction","NOT_YET_RECRUITING","2025-07-17",{"date":62,"type":63},"2025-07-18","ACTUAL",{"date":65,"type":45},"2025-09-01",{"date":67,"type":45},"2028-09-01",{"name":5,"class":6}]